Figure 2.

Response of olaparib-resistant tumors to DNA-damaging agents. A, classification of the response of olaparib-resistant (Res) and control tumors (Ctr) from 5 individual donors (KB1PM1, 3, 4, 5, and 8) to olaparib (50 mg/kg, daily for 28 days), topotecan (2 mg/kg, days 0–4 and 14–18), cisplatin (6 mg/kg, day 0), and doxorubicin (5 mg/kg, days 0, 7, and 14). Untreated tumors would be classified as “poor responders.” B –D, for the same group of mice, the relapse-free survival is shown in response to topotecan, cisplatin, or doxorubicin. The poor and intermediate responders of A have a relapse-free survival of 0 days, as the tumor did not shrink below 50% of the original size. Day 0 is the start of the treatment. The Gehan–Breslow–Wilcoxon P values are indicated.